Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Study Type: Interventional"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Severe+exacerbations%22&type=Subject&filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22
/vufind/Search/Results?lookfor=%22Severe+exacerbations%22&type=Subject&filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22
Search /vufind/Search2/Results?lookfor=%22Severe+exacerbations%22&type=Subject&filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22
PubPharm (23)
1
The treatment failure and clinical efficacy comparison of budesonide metered-dose inhaler and systemic steroid in acute COPD exacerbation : The treatment failure and clinical efficacy comparison of budesonide metered-dose inhaler and systemic steroid in acute COPD exacerbation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
The treatment failure and clinical efficacy comparison of budesonide metered-dose inhaler and systemic steroid in acute COPD exacerbation : The treatment failure and clinical efficacy comparison of budesonide metered-dose inhaler and systemic steroid in acute COPD exacerbation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK : At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK (ARRISA-UK): a pragmatic cluster randomised trial with nested economic and process evaluations examining the effects of integrating at-risk asthma registers into primary care with internet-based training and support
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK : At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK (ARRISA-UK): a pragmatic cluster randomised trial with nested economic and process evaluations examining the effects of integrating at-risk asthma registers into primary care with internet-based training and support
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). : A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). - Phase III, Efficacy and Safety of Kamada-AAT for Inhalation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). : A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). - Phase III, Efficacy and Safety of Kamada-AAT for Inhalation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). : A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). - Phase III, Efficacy and Safety of Kamada-AAT for Inhalation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). : A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). - Phase III, Efficacy and Safety of Kamada-AAT for Inhalation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). : A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). - Phase III, Efficacy and Safety of Kamada-AAT for Inhalation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). : A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% = FEV1 = 80% of predicted; FEV1/SVC = 70%). - Phase III, Efficacy and Safety of Kamada-AAT for Inhalation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
Nächster »
[3]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Study Type: Interventional
Medienart
23
Aufsätze
23
E-Artikel
23
E-Ressourcen
Zeitschriftentitel
22
WHO International Clinical Trials Registry Plat...
1
ClinicalTrials.gov
Thema
23
610
Study Type: Interventional
17
Phase: Phase 3
14
Recruitment Status: Authorised-recruitment may ...
10
Medical Condition: Adult Patients with Congenit...
4
Phase: Phase 4
4
Recruitment Status: Not yet recruiting
4
Recruitment Status: Recruiting
2
Medical Condition: Adult Patients with Congenit...
2
Medical Condition: Asthma care in general pract...
2
Medical Condition: COPD with acute moderate to ...
2
Medical Condition: Health Condition 1: null- Se...
2
Medical Condition: Moderate to severe exacerbat...
2
Medical Condition: Severe exacerbation of chron...
1
Hepatitis
1
Hepatitis B
1
Hepatitis B, Chronic
1
Medical Condition: Chronic HBV With Severe Exac...
1
Recruitment Status: Unknown status
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
22
2020-
1
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
23
Englisch
Haven't found what you're looking for?
Wird geladen...